At the time of writing, Pacific Biosciences of California Inc [PACB] stock is trading at $5.62, up 7.46%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PACB shares have gain 6.24% over the last week, with a monthly amount drifted -19.94%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, PacBio to Present at Upcoming Investor Conferences. In a post published today on Yahoo Finance, PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:.
From an analyst’s perspective:
Pacific Biosciences of California Inc [NASDAQ: PACB] stock has seen the most recent analyst activity on December 14, 2023, when Stephens initiated its Overweight rating and assigned the stock a price target of $11. On December 13, 2023, Wolfe Research initiated with a Peer Perform rating. UBS upgraded its rating to a Buy and decreased its price target to $10 on November 17, 2023. Cantor Fitzgerald upgraded its rating to a Overweight but $11 remained the price target by the analyst firm on October 31, 2023. Bernstein started tracking with a Outperform rating for this stock on September 28, 2023, and assigned it a price target of $11.
For the past year, the stock price of Pacific Biosciences of California Inc fluctuated between $5.00 and $14.55. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Pacific Biosciences of California Inc [NASDAQ: PACB] shares were valued at $5.62 at the most recent close of the market. An investor can expect a potential return of 91.28% based on the average PACB price forecast.
Analyzing the PACB fundamentals
According to Pacific Biosciences of California Inc [NASDAQ:PACB], the company’s sales were 200.52M for trailing twelve months, which represents an 113.35% jump. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.16 points at the first support level, and at 4.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.88, and for the 2nd resistance point, it is at 6.15.
Pacific Biosciences of California Inc [PACB] reported earnings per share of -$0.31 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.28/share, meaning a difference of -$0.03 and a surprise factor of -10.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.26 per share as compared to estimates of -$0.33 per share, a difference of $0.07 representing a surprise of 21.20%.
Ratios To Look Out For
It is important to note that Pacific Biosciences of California Inc [NASDAQ:PACB] has a current ratio of 12.21. As well, the Quick Ratio is 11.27, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 7.50, the price to book ratio is 1.90.
Transactions by insiders
Recent insider trading involved HENRY CHRISTIAN O,, that happened on Feb 20 when 1979.0 shares were sold., Kim Susan G. completed a deal on Feb 20 to sell 831.0 shares. Meanwhile, HENRY CHRISTIAN O sold 79038.0 shares on Feb 16.
